<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12353945
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     09
    </month>
    <day>
     30
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     10
    </month>
    <day>
     08
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1539-3704
     </issn>
     <journalissue citedmedium="Internet">
      <volume>
       137
      </volume>
      <issue>
       7
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Oct
       </month>
       <day>
        1
       </day>
      </pubdate>
     </journalissue>
     <title>
      Annals of internal medicine
     </title>
     <isoabbreviation>
      Ann. Intern. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Statin-associated myopathy with normal creatine kinase levels.
    </articletitle>
    <pagination>
     <medlinepgn>
      581-5
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Muscle symptoms in patients who are treated with statins and have normal creatine kinase levels are not well understood.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Case reports from preliminary analysis of an ongoing clinical trial.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Clinical research center in a community hospital.
     </abstracttext>
     <abstracttext label="PATIENTS" nlmcategory="METHODS">
      Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use.
     </abstracttext>
     <abstracttext label="MEASUREMENTS" nlmcategory="METHODS">
      1) Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      All four patients repeatedly distinguished blinded statin therapy from placebo. Strength testing confirmed weakness during statin therapy that reversed during placebo use. Muscle biopsies showed evidence of mitochondrial dysfunction, including abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy when they were not receiving statins. Creatine kinase levels were normal in all four patients despite the presence of significant myopathy.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Some patients who develop muscle symptoms while receiving statin therapy have demonstrable weakness and histopathologic findings of myopathy despite normal serum creatine kinase levels.
     </abstracttext>
    </abstract>
    <affiliation>
     Interventional Cardiology, Scripps Mercy Hospital and University of California, San Diego, Medical Center, San Diego, California 92103, USA. inquire@impostertrial.com
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Phillips
      </lastname>
      <forename>
       Paul S
      </forename>
      <initials>
       PS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Haas
      </lastname>
      <forename>
       Richard H
      </forename>
      <initials>
       RH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bannykh
      </lastname>
      <forename>
       Sergei
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hathaway
      </lastname>
      <forename>
       Stephanie
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gray
      </lastname>
      <forename>
       Nancy L
      </forename>
      <initials>
       NL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kimura
      </lastname>
      <forename>
       Bruce J
      </forename>
      <initials>
       BJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Vladutiu
      </lastname>
      <forename>
       Georgirene D
      </forename>
      <initials>
       GD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       England
      </lastname>
      <forename>
       John D F
      </forename>
      <initials>
       JD
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       Scripps Mercy Clinical Research Center
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Case Reports
     </publicationtype>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Ann Intern Med
    </medlineta>
    <nlmuniqueid>
     0372351
    </nlmuniqueid>
    <issnlinking>
     0003-4819
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anticholesteremic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Heptanoic Acids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hydroxymethylglutaryl-CoA Reductase Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pyrroles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      110862-48-1
     </registrynumber>
     <nameofsubstance>
      atorvastatin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      75330-75-5
     </registrynumber>
     <nameofsubstance>
      Lovastatin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      79902-63-9
     </registrynumber>
     <nameofsubstance>
      Simvastatin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 2.7.3.2
     </registrynumber>
     <nameofsubstance>
      Creatine Kinase
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2003 Jun 17;138(12):1008; author reply 1008-9
     </refsource>
     <pmid version="1">
      12809468
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2002 Oct 1;137(7):I45
     </refsource>
     <pmid version="1">
      12353973
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2002 Oct 1;137(7):617-8
     </refsource>
     <pmid version="1">
      12353951
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2003 Mar 4;138(5):436-7
     </refsource>
     <pmid version="1">
      12614104
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2003 Jun 17;138(12):1007; author reply 1008-9
     </refsource>
     <pmid version="1">
      12809466
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2003 Jun 17;138(12):1007-8; author reply 1008-9
     </refsource>
     <pmid version="1">
      12809465
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2003 Jun 17;138(12):1007; author reply 1008-9
     </refsource>
     <pmid version="1">
      12809467
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anticholesteremic Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Biopsy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Creatine Kinase
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heptanoic Acids
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydroxymethylglutaryl-CoA Reductase Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lovastatin
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Muscular Diseases
     </descriptorname>
     <qualifiername majortopicyn="Y">
      chemically induced
     </qualifiername>
     <qualifiername majortopicyn="Y">
      enzymology
     </qualifiername>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pain
     </descriptorname>
     <qualifiername majortopicyn="N">
      chemically induced
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pyrroles
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Simvastatin
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      10
     </month>
     <day>
      2
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      10
     </month>
     <day>
      9
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      10
     </month>
     <day>
      2
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12353945
    </articleid>
    <articleid idtype="pii">
     200210010-00009
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

